key: cord-0940459-qx6hhotk
authors: Angurana, Suresh Kumar; Bansal, Arun
title: Probiotics and Coronavirus disease 2019: think about the link
date: 2020-09-14
journal: Br J Nutr
DOI: 10.1017/s000711452000361x
sha: bcbdb2fc5de3b55404e95c71021e2bf583ac42ba
doc_id: 940459
cord_uid: qx6hhotk

[Figure: see text]

gut-lung interaction is bidirectional, and the gut plays a vital role in influencing lung disease. In diseased states, the gut microbiome is disturbed (dysbiosis), leading to translocation of endotoxins and microbial metabolites from the gut, which can then impact the lung through the bloodstream. Similarly, when inflammation occurs in the lungs (e.g. respiratory viral infections), it causes perturbations in the gut microbiome (gut-lung axis) (16, 32, 33) .

This bidirectional gut-lung interaction may be playing an important role in COVID-19, leading to increased disease severity. In extreme of ages and among those with underlying co-morbid conditions, the gut microbiota is less in diversity leading to gut dysbiosis (34) (35) (36) (37) . This could be one of the reasons for the increased disease severity of COVID-19 among cases with the extreme of ages and in those with underlying co-morbid medical conditions (38, 39) . It has been demonstrated that the gut microbiome is altered in cases with COVID-19 in terms of a significant reduction in diversity and number of beneficial gut microbiota and an increase in the number of opportunistic pathogens (16, 40, 41) . This can ultimately lead to gut dysbiosis, translocation of pathogenic organisms across the gut mucosa, secondary bacterial infections, enhanced inflammatory response, multiple organ dysfunction and poor clinical outcome. Zuo et al. (41) performed metagenomic sequencing analyses on the faecal samples of COVID-19 patients (n 15) from the time of admission until discharge and compared them with fifteen healthy controls. The authors demonstrated that these patients had significant depletion of beneficial commensals and enrichment of opportunistic pathogens at the time of admission as well as at all time points during the hospital stay when compared with controls. Similarly, Gu et al. (40) , in a cross-sectional study involving COVID-19 patients (n 30), demonstrated that the gut microbiome (faecal sample collected at admission) of COVID-19 cases had significantly reduced bacterial diversity, a lower count of beneficial symbionts and a higher number of opportunistic pathogens (Streptococcus, Rothia, Veillonella and Actinomyces). Therefore, the heightened or dysregulated inflammation and gut dysbiosis may be the major pathophysiological processes in cases with COVID-19 leading to increased severity of illness and poor clinical outcomes.

The therapies such as antiviral drugs that inhibit the viral entry and/or replication (remdesivir, favipiravir and lopinavirritonavir) and drugs/strategies that modulate the cytokine storm (hydroxychloroquine, chloroquine, azithromycin, JAK inhibitors, IL-6 inhibitors, IL-1 inhibitors, anti-TNF-α agents, corticosteroids, IVIG, tocilizumab, colchicine and plasma therapy) have been the focus of research in COVID-19 but without much clinical success (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (Fig. 1) .

In the absence of proven effective therapy for COVID-19, the treatment is mainly supportive. Therefore, the alternative strategies that target pathophysiological pathways in patients with COVID-19 need to be tested. One such approach is probiotics. The WHO and FAO defined probiotics as 'live microorganisms which, when administered in adequate amounts, confer a health benefit on the host.' Many different micro-organisms have been considered as probiotics, including Lactobacillus species (L. acidophilus, L. casei and L. rhamnosus); Bifidobacterium species (B. bifidum, B. longum and B. lactis); Enterococcus species (E. faecalis and E. faecium) and Saccharomyces (S. boulardii and S. cerevisiae). The most commonly used strains are Lactobacillus and Bifidobacterium (52) .

Probiotics exert their beneficial effects through various mechanisms including manipulation and restoration of gut microbiota, enhancement of intestinal barrier function, competition with pathogens for adhesion to gut epithelium and nutrition, suppression of opportunistic pathogens, production of antimicrobial substances, decrease in translocation of opportunistic organisms, activation of mucosal immunity and modulation of the innate and adaptive immune response (29, (52) (53) (54) (55) (56) (57) . These actions of probiotics have been proven in various experimental (58) (59) (60) and clinical studies (55, (61) (62) (63) (64) (65) (66) .

It is important to note that not all probiotic strains exert the same actions (29) . The combination of multiple strains may exert one or a few of these actions and thus act synergistically. Therefore, multistrain probiotics could be more effective than mono-strain probiotics (67) . A review comparing single strain and multistrain probiotics demonstrated that the multistrain probiotics had greater efficacy than individual strains, including single strains that were components of the mixtures themselves (68) .

Due to the beneficial effects of probiotics on gut microbiota, they have been tested to prevent various infective complications among hospitalised patients. Many strain of probiotics has been demonstrated to be safe and effective in the prevention of Clostridium difficile-associated diarrhoea among hospitalised children and adults (69, 70) and secondary bacterial infections including ventilator-associated pneumonia in critically ill patients (71) (72) (73) (74) , postoperative infections (respiratory, urinary tract and wound infections) in patients undergoing gastrointestinal surgery (75) and candida colonisation in the gastrointestinal tract and invasive candidiasis in critically ill children (52) (53) (54) . Systematic reviews and meta-analysis involving critically ill adults demonstrated that probiotic supplementation has been associated with decreased risk of nosocomial infections, lesser gastrointestinal complications, lower mortality and shortened ICU stays (76) (77) (78) . Among preterm neonates, a meta-analysis (n 8000) demonstrated that supplementation with certain probiotics resulted in a reduction in necrotising enterocolitis, nosocomial sepsis and all-cause mortality (79) .

Since the gut microbiome is altered in cases with COVID-19 (16, 40, 41) , some strain of probiotics may help in restoring the gut microbiota, maintain a healthy gut-lung axis, lesser translocation of pathogenic bacteria across gut mucosa and lesser chances of secondary bacterial infections. Similar actions have been demonstrated in several experimental and clinical studies (55, (58) (59) (60) (61) (62) (63) (64) (65) (66) 80, 81) . The findings of these studies can be extrapolated and need to be tested in cases with COVID-19.

The role of probiotics in the modulation of inflammation has been demonstrated in clinical studies involving children and adults in health and several diseased states (55, 62, 63, 65, 66, (82) (83) (84) (85) . Kazemi et al. (82) , in a recent systematic review and meta-analysis, analysed 167 clinical trials that investigated the effect of oral probiotics or synbiotic (for >1 week) on inflammatory markers (C-reactive protein, IL-1β, IL-4, IL-6, IL-8, IL-10, IL-12, TNF-α, interferon-γ and transforming growth factor-β) among healthy individuals and in various disease conditions. Authors noted that some probiotics lead to decrease in C-reactive protein levels in healthy individuals, metabolic disorders, inflammatory bowel disease, arthritis and critically ill condition; decrease in TNF-α levels in healthy individuals, fatty liver, inflammatory bowel disease and hepatic cirrhosis; increase in IL-6 in cirrhosis and renal failure; and increase in IL-10 in arthritis. In another meta-analysis (eight clinical trials, 1337 patients with diabetes), it has been demonstrated that probiotics and synbiotic supplementation significantly decreased C-reactive protein and TNF-α levels but did not affect IL-6 levels (83) . These meta-analyses suggest that supplementation with probiotics leads to a decrease in proinflammatory markers (hs-C-reactive protein, TNF-a, IL-6, IL-12, IL-4 and TNF-α) and an increase in anti-inflammatory cytokines (IL-10) in healthy and several diseased states (82) (83) (84) .

In an RCT (n 100), Angurana et al. (55) demonstrated that administration of a multistrain probiotic (Lactobacillus paracasei, L. plantarum, L. acidophilus, L. delbrueckii, Bifidobacterium longum, B. infantis, B. breve and Streptococcus salivarius) to critically ill children with severe sepsis for 7 days resulted in a significant decrease in levels of pro-inflammatory cytokines (IL-6, IL-12p70, IL-17 and TNF-α) and increase in antiinflammatory cytokines (IL-10 and transforming growth factor-β 1) as compared with placebo. Other studies also demonstrated that certain probiotics were useful in the modulation of inflammation in critically ill patients (66, 85) .

As cytokine storm occurs in patients with severe COVID-19, the effect of probiotics on pro-inflammatory and immunoregulatory cytokines allows viral clearance and minimise immune response-mediated tissue damage in the lungs and other organs. So, these immune-modulatory effects of probiotics might be relevant to prevent lung injury, acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome which are significant complications of COVID-19 (29) .

The antiviral effects of probiotics have been demonstrated in experimental and clinical studies. Few experimental studies showed that various strains of probiotics exert antiviral effect by impairing virus entry into human cells and preventing viral replication (86) (87) (88) (89) . Ang et al. (86) , in an in vitro study involving human skeletal muscle and colon cell lines, demonstrated that Lactobacillus reuteri Protectis showed significant dosedependent antiviral activity against Coxsackievirus type A strains 6 and 16 and enterovirus 71. Lee et al. (87) Viruses are the most frequent cause of upper respiratory tract infections. A Cochrane review (twelve RCT with 3720 participants, including children and adults) showed that probiotics were superior to placebo in decreasing the number of participants experiencing episodes of acute upper respiratory tract infections, mean duration of an episode of acute upper respiratory tract infections, antibiotic use and cold-related school absenteeism (95) . In influenza viral infection, probiotics have been shown to modulate respiratory immunity and had a beneficial impact on virus clearance and inflammatory-mediated lung injury (96) .

Recently, Anwar et al. (88) , in a computational docking study, demonstrated that three metabolites of Lactobacillus plantarum (Plantaricin W, Plantaricin JLA-9 and Plantaricin D) significantly blocked the binding of SARS-CoV-2 with angiotensin-converting enzyme 2 receptors (blocking the viral entry into the cells) and suggested antiviral property of Lactobacillus plantarum against SARS-CoV-2.

Therefore, probiotics may act as antiviral agents by interfering with the viral entry into cells and/or inhibit virus replication. This may lead to a reduction in the dissemination of SARS-CoV-2 in the respiratory tract and gut. Also, with the restoration of the gut and respiratory microbiota, immune function and gut-lung axis, the course of COVID-19 may be altered (29) .

Most of the probiotic strains are generally safe even in the vulnerable population and in an intensive care setting, including neonates, children and adults. Many probiotic strains have shown beneficial effects in these settings (52) (53) (54) (55) (61) (62) (63) (64) (65) (66) (69) (70) (71) (72) (73) (74) (75) (76) (77) (78) (79) (82) (83) (84) (85) 97) . However, there are few case reports of probiotic-associated bacteraemia, infective endocarditis, liver abscesses and fungaemia. These are majorly reported in severely debilitated cases, premature babies and immunocompromised patients who were treated with preparations lacking adequate quality control (98) (99) (100) (101) (102) (103) (104) .

It has been suggested to exercise caution while using probiotics in the presence of a one major risk factor (immunocompromised state and premature infants) or more than one minor risk factor (central venous catheter, cardiac valvular disease, impaired intestinal epithelial barrier, administration of probiotics by jejunostomy and probiotics with properties of high mucosal adhesion or known pathogenicity) because of the risk of probiotics-sepsis (80, 105) .

Other safety concerns are the genetic transfer of antimicrobial resistance from probiotic strains to pathogenic organisms in the gut (particularly Staphylococcus aureus and Enterococcus) (106, 107) , deleterious metabolic activities and excessive immune stimulation in susceptible individuals (52, 80) . The use of probiotics may be limited in the presence of immunocompromised states or premature neonates because of safety concerns, as discussed above. The supplementation with probiotics may not be possible in whom enteral administration is contraindicated.

The rationale for using probiotics in Coronavirus disease 2019

Several clinical trials of antiviral and anti-inflammatory drugs are in progress to evaluate the therapeutic effects of these drugs in patients with COVID-19 (108) . The site of action of currently used antiviral and anti-inflammatory medications is at limited steps in the pathogenesis of COVID-19 (Fig. 1) . The probiotics, such as Lactobacillus and Bifidobacterium, possibly act at multiple levels in this cascade of COVID-19. They act through antiviral actions (86) (87) (88) (89) (90) (91) (92) (93) (94) (95) (96) , restoration of the gut microbiome (55, (58) (59) (60) (61) (62) (63) (64) (65) (66) 80, 81) , modulation of inflammation/cytokine storm (anti-inflammatory) (55, 62, 63, 65, 66, (82) (83) (84) (85) and prevention of secondary bacterial and fungal infections (52) (53) (54) (69) (70) (71) (72) (73) (74) (75) (Fig. 1) . Though the evidence for the rationale of using probiotics to treat COVID-19 comes from indirect evidence, these actions of probiotics may help in the prevention of and/or alleviation of COVID-19 related symptoms and complications. Moreover, probiotics are readily available, easy to administer (oral administration), relatively safe and economical compared with antiviral drugs, immunomodulators or other strategies tested in COVID-19 (1) .

Therefore, probiotics, due to their mechanisms of action, are a potential strategy that need to be tested in moderate to severe cases with COVID-19 by conducting well-designed clinical trials. Few registered trials are going on to evaluate the possible beneficial effects of probiotics supplementation in cases with COVID-19 (NCT04366180, NCT04368351 and NCT04366089).

A better understanding of the pathophysiology of COVID-19 and the results of the clinical trials will guide further on the efficacy, benefits and safety of probiotics in COVID-19. Despite these limitations, considering various mechanisms of actions of probiotics on the regulation of gut dysbiosis and anti-inflammatory activity, and clinical evidence about the beneficial effects of probiotics in critically ill adults and children, probiotics are a potential therapeutic strategy that need to be tested in moderate to severe cases with COVID-19.

Some probiotics may have a beneficial role in the treatment of COVID-19 patients due to their antiviral activity, ability to restore gut microbiome, modulate inflammation, ready availability, ease of administration, relatively safe and economical. The recommendations regarding the strain, dose and duration of probiotic are lacking. However, given the large experience of clinical usage, and evidence for beneficial effects in the various clinical settings, Lactobacillus and Bifidobacterium can safely be used.

Diet supplementation, probiotics, and nutraceuticals in SARS-CoV-2 infection: a Scoping Review

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review

SARS-CoV-2 infection in children

Clinical features and outcome of SARS-CoV-2 infection in children: a systematic review and meta-analysis

The clinical characteristics of pediatric inpatients with SARS-CoV-2 infection: a meta-analysis and systematic review

Clinical course and outcomes of 344 intensive care patients with COVID-19

ICU and ventilator mortality among critically Ill adults with coronavirus disease 2019

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts

Clinical and immune features of hospitalized pediatric patients with Coronavirus Disease

Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment

Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort

Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2

Gut microbiota and Covid-19-possible link and implications

Targeting the gut-lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection

Hyperinflammatory shock in children during COVID-19 pandemic

Multisystem inflammatory syndrome in US children and adolescents

SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study

Gastrointestinal symptoms as a major presentation component of a novel multisystem inflammatory syndrome in children (MIS-C) that is related to COVID-19: a single center experience of 44 cases

Multisystem Inflammatory Syndrome in Children (MIS-C) associated with SARS-CoV-2 infection: a multi-institutional study from New York City

Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic

Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Detection and isolation of SARS-CoV-2 in serum, urine, and stool specimens of COVID-19 patients from the Republic of Korea

The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients

Detection of SARS-CoV-2 in fecal samples from patients with asymptomatic and mild COVID-19 in Korea

Using probiotics to flatten the curve of coronavirus disease COVID-2019 pandemic. Front Public Health 8

Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection

Extrapulmonary manifestations of COVID-19

The role of the lung microbiota and the gut-lung axis in respiratory infectious diseases

Pulmonary-intestinal crosstalk in mucosal inflammatory disease

The human intestinal microbiome at extreme ages of life. Dietary intervention as a way to counteract alterations

From lifetime to evolution: timescales of human gut microbiota adaptation

Characterizing the composition of the pediatric gut microbiome: a systematic review

Studying the gut microbiome of Latin America and Hispanic/Latino populations. Insight into obesity and diabetes: systematic review

Pediatric COVID-19: systematic review of the literature

Clinical characteristics of coronavirus disease 2019 in China

Alterations of the gut microbiota in patients with COVID-19 or H1N1 influenza

Alterations in gut microbiota of patients with COVID-19 during time of hospitalization

IL-6 inhibitors in the treatment of serious COVID-19: a promising therapy

A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19

Observational study of hydroxychloroquine in hospitalized patients with Covid-19

Remdesivir for the treatment of Covid-19 -Final Report

Remdesivir for 5 or 10 days in patients with severe covid-19

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19

Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: a case series

Early safety indicators of COVID-19 convalescent plasma in 5,000 patients

Clinical outcomes in COVID-19 patients treated with tocilizumab: an individual patient data systematic review

Role of probiotics in prevention of Candida infection in critically ill children

Probiotic use and prevalence of candidemia and candiduria in a PICU

Evaluation of efficacy of probiotics in prevention of candida colonization in a PICU-a randomized controlled trial

Evaluation of effect of probiotics on cytokine levels in critically Ill children with severe sepsis: a double-blind, placebo-controlled trial

Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review

Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials

Evaluation of the preventative effects exerted by Lactobacillus fermentum in an experimental model of septic shock induced in mice

Cytokines and tolllike receptor signaling pathways in the terminal ileum of hypoxic/hyperoxic neonatal rats: benefits of probiotics supplementation

Lactobacillus rhamnosus GG and Bifidobacterium longum attenuate lung injury and inflammatory response in experimental sepsis

The immunomodulatory properties of viable Lactobacillus salivarius ssp. salivarius CECT5713 are not restricted to the large intestine

A prospective randomised trial of probiotics in critically ill patients

Gut microbial translocation in critically ill children and effects of supplementation with pre-and pro biotics

Effect of a multispecies probiotic on inflammatory markers in critically ill patients: a randomized, double-blind, placebo-controlled trial

Design of a multispecies probiotic mixture to prevent infectious complications in critically ill patients

Monostrain, multistrain and multispecies probiotics -a comparison of functionality and efficacy

Health benefits of probiotics: are mixtures more effective than single strains?

Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children

Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: a systematic review with meta-regression analysis

Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis

Manipulation of the microbiome in critical illness-probiotics as a preventive measure against ventilator-associated pneumonia

Probiotics for preventing ventilator-associated pneumonia

Probiotics for the prevention of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials

Effect of perioperative probiotics and synbiotics on postoperative infections after gastrointestinal surgery: a systematic review with meta-analysis

Early enteral nutrition supplemented with probiotics improved the clinical outcomes in severe head injury: some promising findings from Chinese patients

The effects of probiotics in early enteral nutrition on the outcomes of trauma: a meta-analysis of randomized controlled trials

Impact of the administration of probiotics on mortality in critically ill adult patients: a meta-analysis of randomized controlled trials

The "golden age" of probiotics: a systematic review and meta-analysis of

Angurana and A. Bansal randomized and observational studies in preterm infants

Probiotics in critically ill children. F1000Res 5, F1000 Faculty Rev-407

Therapeutic potential of the gut microbiota in the prevention and treatment of sepsis

Effect of probiotic and synbiotic supplementation on inflammatory markers in health and disease status: a systematic review and metaanalysis of clinical trials

The effects of probiotic and synbiotic supplementation on inflammatory markers among patients with diabetes: a systematic review and meta-analysis of randomized controlled trials

The effect of probiotics on inflammatory biomarkers: a meta-analysis of randomized clinical trials

Effect of enteral nutrition and ecoimmunonutrition on bacterial translocation and cytokine production in patients with severe acute pancreatitis

Antiviral activity of Lactobacillus reuteri protectis against Coxsackievirus A and Enterovirus 71 infection in human skeletal muscle and colon cell lines

Probiotic bacteria, B. longum and L. acidophilus inhibit infection by Rotavirus in vitro and decrease the duration of diarrhea in pediatric patients

Antiviral effects of probiotic metabolites on COVID-19

Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium Lactobacillus gasseri SBT2055

Nasal priming with immunobiotic lactobacilli improves the adaptive immune response against influenza virus

Nasal priming with immunobiotic Lactobacillus rhamnosus modulates inflammation-coagulation interactions and reduces influenza virus-associated pulmonary damage

Nasally administered Lactobacillus rhamnosus strains differentially modulate respiratory antiviral immune responses and induce protection against respiratory syncytial virus infection

Intestinal innate antiviral immunity and immunobiotics: beneficial effects against rotavirus infection

Development of an in vitro immunobiotic evaluation system against rotavirus infection in bovine intestinal epitheliocytes

Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev

Respiratory antiviral immunity and immunobiotics: beneficial effects on inflammation-coagulation interaction during influenza virus infection

Probiotic use in at-risk populations

Bifidobacterium longum subspecies infantis Bacteremia in 3 extremely preterm infants receiving probiotics

Commercial probiotic products: a call for improved quality control. A position paper by the ESPGHAN working group for probiotics and prebiotics

Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases

Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG

Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis

Saccharomyces cerevisiae fungemia: an emerging infectious disease

Possible role of catheters in Saccharomyces boulardii fungemia

Probiotic use in clinical practice: what are the risks?

Antibiotic susceptibility profiles of Lactobacillus reuteri and Lactobacillus fermentum

Identification and characterization of antibiotic resistance genes in Lactobacillus reuteri and Lactobacillus plantarum

Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19)

The authors declare that there are no conflicts of interest.Both authors contribute significantly to this manuscript.